ORLANDO — At 48 weeks, MCO-010, an optogenetic therapy, demonstrated gains in visual acuity in Stargardt disease, according to a study presented at the American Academy of Ophthalmology meeting.
We live as if the world owes us permanence. We hold tightly to relationships, jobs, moments of success, and even to our own identities, believing they are ours to keep. And yet, if life teaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback